董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Douglas Jay Cohen | 男 | Lead Independent Director and Independent Director | 55 | 13.10万美元 | 2.53 | 2026-06-15 |
| David Gobel | 男 | Director | 73 | 13.10万美元 | 1.94 | 2026-06-15 |
| Alison Tjosvold Milhous | 女 | Director | 47 | 13.10万美元 | 2.43 | 2026-06-15 |
| Keith Murphy | 男 | Director and Executive Chairman of the Board | 54 | 97.35万美元 | 6.24 | 2026-06-15 |
| Adam Stern | 男 | Director | 62 | 12.29万美元 | 2.43 | 2026-06-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Norman Staskey | 男 | Chief Financial Officer and President | 55 | 11.95万美元 | 未持股 | 2026-06-15 |
| Tony Lialin | 男 | Chief Commercial Officer | 55 | 29.80万美元 | 1.00 | 2026-06-15 |
| Amar Sethi | 男 | Chief Scientific Officer | 55 | 23.53万美元 | 未持股 | 2026-06-15 |
| Amar Sethi | 男 | Chief Scientific Officer | 55 | 未披露 | 未持股 | 2026-06-15 |
| Keith Murphy | 男 | Director and Executive Chairman of the Board | 54 | 97.35万美元 | 6.24 | 2026-06-15 |
董事简历
中英对照 | 中文 | 英文- Douglas Jay Cohen
-
Douglas Jay Cohen自2020年9月起在公司董事会任职，自2022年9月起担任公司首席独立董事。自2019年1月起，他担任IR Medtek LLC的总裁兼首席执行官，该公司是一家医疗设备公司，使用俄亥俄州立大学许可的技术开发用于初级保健医生癌症检测的非侵入性探针。在加入IR Medtek之前，科恩先生于2016年9月至2019年1月担任先进技术印刷公司Beacon Street Innovations的总裁兼首席执行官。1994年1月至2016年9月，科恩先生在工业和建筑重型设备制造商Screen Machine Industries担任运营和工程副总裁。作为一名活跃于创业公司的投资者，科恩先生在过去10年中投资了20多家生物技术初创公司，包括在2013年投资该公司的公司并一直保持在该公司的地位。科恩先生获得了麻省理工学院的学士学位。
Douglas Jay Cohen has served on the company's Board since September 2020 and has served as the company's Lead Independent Director since September 2022. Since January 2019, he has served as President and Chief Executive Officer of IR Medtek LLC, a medical device company developing a non invasive probe for cancer detection by primary care physicians using technology licensed from The Ohio State University. Prior to IR Medtek, Mr. Cohen served as President and Chief Executive Officer of Beacon Street Innovations, an advanced technology printing company, from September 2016 to January 2019. From January 1994 to September 2016, Mr. Cohen served as Vice President of Operations and Engineering at Screen Machine Industries, an industrial and construction heavy equipment manufacturer. As an active investor in startup companies, Mr. Cohen has invested in more than 20 biotech startups in the past 10 years, including investing in the company's Company in 2013 and maintaining a position in the Company ever since. Mr. Cohen received a B.S. from the Massachusetts Institute of Technology. - Douglas Jay Cohen自2020年9月起在公司董事会任职，自2022年9月起担任公司首席独立董事。自2019年1月起，他担任IR Medtek LLC的总裁兼首席执行官，该公司是一家医疗设备公司，使用俄亥俄州立大学许可的技术开发用于初级保健医生癌症检测的非侵入性探针。在加入IR Medtek之前，科恩先生于2016年9月至2019年1月担任先进技术印刷公司Beacon Street Innovations的总裁兼首席执行官。1994年1月至2016年9月，科恩先生在工业和建筑重型设备制造商Screen Machine Industries担任运营和工程副总裁。作为一名活跃于创业公司的投资者，科恩先生在过去10年中投资了20多家生物技术初创公司，包括在2013年投资该公司的公司并一直保持在该公司的地位。科恩先生获得了麻省理工学院的学士学位。
- Douglas Jay Cohen has served on the company's Board since September 2020 and has served as the company's Lead Independent Director since September 2022. Since January 2019, he has served as President and Chief Executive Officer of IR Medtek LLC, a medical device company developing a non invasive probe for cancer detection by primary care physicians using technology licensed from The Ohio State University. Prior to IR Medtek, Mr. Cohen served as President and Chief Executive Officer of Beacon Street Innovations, an advanced technology printing company, from September 2016 to January 2019. From January 1994 to September 2016, Mr. Cohen served as Vice President of Operations and Engineering at Screen Machine Industries, an industrial and construction heavy equipment manufacturer. As an active investor in startup companies, Mr. Cohen has invested in more than 20 biotech startups in the past 10 years, including investing in the company's Company in 2013 and maintaining a position in the Company ever since. Mr. Cohen received a B.S. from the Massachusetts Institute of Technology.
- David Gobel
-
David Gobel自2020年9月起在公司董事会任职。他自2016年12月起担任Methuselah Fund LLC首席执行官，自2001年9月起担任Methuselah Foundation首席执行官，通过各种方式促进增加人类的健康寿命，包括：绩效奖、定向赠款、教育以及创建/资助生物技术初创公司。Gobel先生于2009年1月至2013年3月期间成为运输安全管理局的首席风险策略师，负责战略规划、创新管理以及通过与In Q Tel合作为TSA和国土安全部创建新颖的风险投资能力。Gobel先生于2018年4月至2020年1月期间担任Volumetric Biotechnologies的董事会成员，该公司是一家专注于生物全息人体组织打印开发的公司。2018年7月至2026年7月，Gobel先生担任Turn Bio的董事会成员，并于2020年5月至2026年7月担任Turn Bio的董事会主席。Gobel先生于2015年10月至2022年8月担任Leucadia Therapeutics的董事会成员，并自2014年12月起担任Oisin Therapeutics的独立创始董事会成员。
David Gobel has served on the company's Board since September 2020. He has served as Chief Executive Officer of Methuselah Fund LLC since December 2016 and as Chief Executive Officer of Methuselah Foundation since September 2001, promoting increasing the healthy human lifespan by various means including: performance prizes, targeted grant making, education, and the creation/funding of biotech startups. Mr. Gobel became Chief Venture Strategist at Transportation Security Administration from January 2009 until March 2013, where he was responsible for strategic planning, innovation management and creation of a novel Venture Capital capability for TSA and then Department of Homeland Security by partnering with In Q Tel. Mr. Gobel was a member of the board of Volumetric Biotechnologies, a company that focuses on the development of bioholographic human tissue printing, from April 2018 to January 2020. From July 2018 to July 2026, Mr. Gobel served as member of the board for Turn Bio, and from May 2020 to July 2026, served as chairman of the board of Turn Bio. Mr. Gobel served as a board member of Leucadia Therapeutics from October 2015 to August 2022, and as an independent founding board member of Oisin Therapeutics since December 2014. - David Gobel自2020年9月起在公司董事会任职。他自2016年12月起担任Methuselah Fund LLC首席执行官，自2001年9月起担任Methuselah Foundation首席执行官，通过各种方式促进增加人类的健康寿命，包括：绩效奖、定向赠款、教育以及创建/资助生物技术初创公司。Gobel先生于2009年1月至2013年3月期间成为运输安全管理局的首席风险策略师，负责战略规划、创新管理以及通过与In Q Tel合作为TSA和国土安全部创建新颖的风险投资能力。Gobel先生于2018年4月至2020年1月期间担任Volumetric Biotechnologies的董事会成员，该公司是一家专注于生物全息人体组织打印开发的公司。2018年7月至2026年7月，Gobel先生担任Turn Bio的董事会成员，并于2020年5月至2026年7月担任Turn Bio的董事会主席。Gobel先生于2015年10月至2022年8月担任Leucadia Therapeutics的董事会成员，并自2014年12月起担任Oisin Therapeutics的独立创始董事会成员。
- David Gobel has served on the company's Board since September 2020. He has served as Chief Executive Officer of Methuselah Fund LLC since December 2016 and as Chief Executive Officer of Methuselah Foundation since September 2001, promoting increasing the healthy human lifespan by various means including: performance prizes, targeted grant making, education, and the creation/funding of biotech startups. Mr. Gobel became Chief Venture Strategist at Transportation Security Administration from January 2009 until March 2013, where he was responsible for strategic planning, innovation management and creation of a novel Venture Capital capability for TSA and then Department of Homeland Security by partnering with In Q Tel. Mr. Gobel was a member of the board of Volumetric Biotechnologies, a company that focuses on the development of bioholographic human tissue printing, from April 2018 to January 2020. From July 2018 to July 2026, Mr. Gobel served as member of the board for Turn Bio, and from May 2020 to July 2026, served as chairman of the board of Turn Bio. Mr. Gobel served as a board member of Leucadia Therapeutics from October 2015 to August 2022, and as an independent founding board member of Oisin Therapeutics since December 2014.
- Alison Tjosvold Milhous
-
Alison Tjosvold Milhous自2020年9月起担任公司董事会成员。拥有超20年审计、财务、技术会计经验，注册会计师。她目前在临床阶段精准肿瘤学公司Erasca, Inc.担任会计部高级副总裁。在加入Erasca之前，她是一名独立顾问，主要在生命科学和技术行业内协助有会计和报告需求的公共和私营公司。Milhous女士曾在2015年8月至2019年9月期间担任Grant Thornton LLP的审计合伙人，自2002年以来，她在Grant Thornton担任过越来越多的职务，责任越来越大。她于2000年6月在Arthur Andersen LLP开始了她的职业生涯。Milhous女士在圣路易斯奥比斯波的加州州立理工大学获得了会计和金融双专业的工商管理理学学士学位。
Alison Tjosvold Milhous has served on the company's Board since September 2020. She has over 20 years of audit, financial and technical accounting experience, and is a certified public accountant. She is currently the Senior Vice President of Accounting at Erasca, Inc., a clinical stage precision oncology company. Prior to joining Erasca, she was an independent consultant assisting public and private companies with accounting and reporting needs primarily within the life sciences and technology industries. Ms. Milhous was previously an audit partner at Grant Thornton LLP from August 2015 through September 2019 and held various positions with increasing responsibility at Grant Thornton since 2002. She began her career in June 2000 at Arthur Andersen LLP. Ms. Milhous received a Bachelor of Science degree in Business Administration with a dual concentration in Accounting and Finance from California State Polytechnic University, San Luis Obispo. - Alison Tjosvold Milhous自2020年9月起担任公司董事会成员。拥有超20年审计、财务、技术会计经验，注册会计师。她目前在临床阶段精准肿瘤学公司Erasca, Inc.担任会计部高级副总裁。在加入Erasca之前，她是一名独立顾问，主要在生命科学和技术行业内协助有会计和报告需求的公共和私营公司。Milhous女士曾在2015年8月至2019年9月期间担任Grant Thornton LLP的审计合伙人，自2002年以来，她在Grant Thornton担任过越来越多的职务，责任越来越大。她于2000年6月在Arthur Andersen LLP开始了她的职业生涯。Milhous女士在圣路易斯奥比斯波的加州州立理工大学获得了会计和金融双专业的工商管理理学学士学位。
- Alison Tjosvold Milhous has served on the company's Board since September 2020. She has over 20 years of audit, financial and technical accounting experience, and is a certified public accountant. She is currently the Senior Vice President of Accounting at Erasca, Inc., a clinical stage precision oncology company. Prior to joining Erasca, she was an independent consultant assisting public and private companies with accounting and reporting needs primarily within the life sciences and technology industries. Ms. Milhous was previously an audit partner at Grant Thornton LLP from August 2015 through September 2019 and held various positions with increasing responsibility at Grant Thornton since 2002. She began her career in June 2000 at Arthur Andersen LLP. Ms. Milhous received a Bachelor of Science degree in Business Administration with a dual concentration in Accounting and Finance from California State Polytechnic University, San Luis Obispo.
- Keith Murphy
-
Keith Murphy，重新加入Organovo Holdings， Inc.。他曾担任Organovo Holdings， Inc.的董事。自2020年9月起担任执行主席。他是Viscient Biosciences， Inc.（“Viscient”）的首席执行官兼董事长，这是他于2017年创立的一家私营公司，专注于利用3D组织技术和多组学（基因组学、转录组学、代谢组学）的药物发现和开发。2012年2月至2017年4月，他担任Organovo的总裁兼首席执行官；2012年2月至2017年8月，担任董事长。2007年8月至2012年2月，他曾担任Organovo， Inc. （Organovo的主要运营公司，上市交易前）的总裁、首席执行官和董事长。在创立Organovo之前，从1997年8月到2007年7月，Murphy先生在Amgen， Inc.担任各种职务，包括骨质疏松症/骨癌药物Prolia/Xgeva （denosumab）的全球运营主管。加入Amgen之前，从1993年7月到1997年7月，Murphy先生在Alkermes， Inc.（生物技术公司）任职，在那里他担任他们的第一个批准产品Nutropin （hGH） Depot的开发团队的角色。Murphy先生从2020年8月到2022年2月担任Kintara Therapeutics， Inc.的董事会成员，并在其薪酬委员会、提名和公司治理委员会任职。他持有麻省理工学院化学工程学士学位，是加州大学洛杉矶分校安德森管理学院的校友。
Keith Murphy re joined the company's Board in July 2020 and has served as the company's Executive Chairman since September 2020. Mr. Murphy is the Chief Executive Officer and Chairman of Viscient Biosciences, Inc. ("Viscient"), a private company that he founded in 2017 that is focused on drug discovery and development utilizing 3D tissue technology and multi omics (genomics, transcriptomics, metabolomics). Mr. Murphy previously served as the company's President and Chief Executive Officer from February 2012 through April 2017, and as Chairman from February 2012 through August 2017. Mr. Murphy also previously served as President, Chief Executive Officer, and Chairman of Organovo, Inc., the company's primary operating company prior to its going public transaction, from August 2007 to February 2012. Prior to founding Organovo, Inc., Mr. Murphy served in various roles at Amgen, Inc. from August 1997 to July 2007 including as Global Operations Leader for the osteoporosis/bone cancer drug Prolia/Xgeva (denosumab). Prior to joining Amgen, Mr. Murphy served at Alkermes, Inc., a biotechnology company, from July 1993 to July 1997, where he played a role on the development team for their first approved product, Nutropin (hGH) Depot. Mr. Murphy has served as a member of the board of directors of Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) since March 2025 and served as a member of the board of directors of Kintara Therapeutics, Inc. from August 2020 to February 2022, and served on its compensation committee and nominating and corporate governance committee. He holds a B.S. in Chemical Engineering from MIT and is an alumnus of the UCLA Anderson School of Management. - Keith Murphy，重新加入Organovo Holdings， Inc.。他曾担任Organovo Holdings， Inc.的董事。自2020年9月起担任执行主席。他是Viscient Biosciences， Inc.（“Viscient”）的首席执行官兼董事长，这是他于2017年创立的一家私营公司，专注于利用3D组织技术和多组学（基因组学、转录组学、代谢组学）的药物发现和开发。2012年2月至2017年4月，他担任Organovo的总裁兼首席执行官；2012年2月至2017年8月，担任董事长。2007年8月至2012年2月，他曾担任Organovo， Inc. （Organovo的主要运营公司，上市交易前）的总裁、首席执行官和董事长。在创立Organovo之前，从1997年8月到2007年7月，Murphy先生在Amgen， Inc.担任各种职务，包括骨质疏松症/骨癌药物Prolia/Xgeva （denosumab）的全球运营主管。加入Amgen之前，从1993年7月到1997年7月，Murphy先生在Alkermes， Inc.（生物技术公司）任职，在那里他担任他们的第一个批准产品Nutropin （hGH） Depot的开发团队的角色。Murphy先生从2020年8月到2022年2月担任Kintara Therapeutics， Inc.的董事会成员，并在其薪酬委员会、提名和公司治理委员会任职。他持有麻省理工学院化学工程学士学位，是加州大学洛杉矶分校安德森管理学院的校友。
- Keith Murphy re joined the company's Board in July 2020 and has served as the company's Executive Chairman since September 2020. Mr. Murphy is the Chief Executive Officer and Chairman of Viscient Biosciences, Inc. ("Viscient"), a private company that he founded in 2017 that is focused on drug discovery and development utilizing 3D tissue technology and multi omics (genomics, transcriptomics, metabolomics). Mr. Murphy previously served as the company's President and Chief Executive Officer from February 2012 through April 2017, and as Chairman from February 2012 through August 2017. Mr. Murphy also previously served as President, Chief Executive Officer, and Chairman of Organovo, Inc., the company's primary operating company prior to its going public transaction, from August 2007 to February 2012. Prior to founding Organovo, Inc., Mr. Murphy served in various roles at Amgen, Inc. from August 1997 to July 2007 including as Global Operations Leader for the osteoporosis/bone cancer drug Prolia/Xgeva (denosumab). Prior to joining Amgen, Mr. Murphy served at Alkermes, Inc., a biotechnology company, from July 1993 to July 1997, where he played a role on the development team for their first approved product, Nutropin (hGH) Depot. Mr. Murphy has served as a member of the board of directors of Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) since March 2025 and served as a member of the board of directors of Kintara Therapeutics, Inc. from August 2020 to February 2022, and served on its compensation committee and nominating and corporate governance committee. He holds a B.S. in Chemical Engineering from MIT and is an alumnus of the UCLA Anderson School of Management.
- Adam Stern
-
Adam Stern自2020年3月1日起担任达里奥健康公司董事。Stern先生自2012年起担任Aegis Capital Corp.的私人股本银行业务主管和SternAegis Ventures的首席执行官，并在2011年10月至2014年5月期间担任Dariohealth Corp.董事会成员。在加入Aegis公司之前，1997年至2012年11月，他曾任职于Spencer Trask Ventures，Inc.，最近担任高级董事总经理，负责管理主要专注于技术和生命科学领域的结构性金融集团。1989年至1997年，Stern先生在纽约证券交易所会员Josephthal & Co.，Inc.担任越来越负责的职务，担任高级副总裁兼私募股权营销董事总经理。他自1987年以来一直是FINRA持牌证券经纪人，自1991年以来一直是普通证券负责人。Stern先生是Aerami Therapeutics Holdings（前身为Dance Biopharm，Inc.）、Matinas BioPharma Holdings，Inc.、Adgero Biopharmaceuticals Holdings和Hydrofarm Holdings Group, Inc.的董事。Stern先生是InVivo Therapeutics Holdings Corp.（OTCQB：NVIV）、Organovo Holdings, Inc.（NYSE MKT：ONVO）和Prolor Biotech Ltd.的前任董事，后者于2013年以约6亿美元的价格出售给Opko Health，Inc.（NYSE：OPK）。Stern先生在坦帕的南佛罗里达大学以优异的成绩获得文学学士学位。
Adam Stern Director, re joined Vivosim Labs, Inc.'s Board in July 2020. Mr. Stern is Head of Private Equity, Merchant & Venture Banking (MVB) at ThinkEquity, LLC. since February 2026 and leads the formation and strategic development of ThinkStern Ventures. Prior to ThinkEquity, he was CEO of SternAegis Ventures from December 2012 to February 2026 and had been the Head of Private Equity Banking at Aegis Capital Corp from December 2012 to February 2026. Prior to SternAegis, Mr. Stern served as Senior Managing Director at Spencer Trask Ventures, Inc., a private equity and venture firm, from 1997 to 2012, where he managed the structured finance group focusing primarily on technology and life sciences companies. From 1989 to 1997, Mr. Stern was at Josephthal & Co., Inc., Members of the New York Stock Exchange, where he served as Head of Private Equity and Managing Director. He has been a FINRA licensed securities broker since 1987 and a Registered General Securities Principal since 1991. Mr. Stern previously served as a director of VivoSim from February 2012 to June 2013. Mr. Stern is a current director at DarioHealth Corp. (Nasdaq: DRIO), privately held Amplifica Holdings, Group, Inc., and Aerami Therapeutics Holdings Inc. Mr. Stern is a former director of Adgero Biopharmaceuticals Holdings, Matinas BioPharma Holdings, Inc. (NYSE: MTNB), Hydrofarm Holdings Group Inc. (Nasdaq: HYFM), InVivo Therapeutics, Inc. (Nasdaq: NVIV) and PROLOR Biotech prior to its sale in 2013 to Opko Health, Inc. (Nasdaq: OPK). Mr. Stern graduated with a Bachelor of Arts degree from the University of South Florida in 1987. - Adam Stern自2020年3月1日起担任达里奥健康公司董事。Stern先生自2012年起担任Aegis Capital Corp.的私人股本银行业务主管和SternAegis Ventures的首席执行官，并在2011年10月至2014年5月期间担任Dariohealth Corp.董事会成员。在加入Aegis公司之前，1997年至2012年11月，他曾任职于Spencer Trask Ventures，Inc.，最近担任高级董事总经理，负责管理主要专注于技术和生命科学领域的结构性金融集团。1989年至1997年，Stern先生在纽约证券交易所会员Josephthal & Co.，Inc.担任越来越负责的职务，担任高级副总裁兼私募股权营销董事总经理。他自1987年以来一直是FINRA持牌证券经纪人，自1991年以来一直是普通证券负责人。Stern先生是Aerami Therapeutics Holdings（前身为Dance Biopharm，Inc.）、Matinas BioPharma Holdings，Inc.、Adgero Biopharmaceuticals Holdings和Hydrofarm Holdings Group, Inc.的董事。Stern先生是InVivo Therapeutics Holdings Corp.（OTCQB：NVIV）、Organovo Holdings, Inc.（NYSE MKT：ONVO）和Prolor Biotech Ltd.的前任董事，后者于2013年以约6亿美元的价格出售给Opko Health，Inc.（NYSE：OPK）。Stern先生在坦帕的南佛罗里达大学以优异的成绩获得文学学士学位。
- Adam Stern Director, re joined Vivosim Labs, Inc.'s Board in July 2020. Mr. Stern is Head of Private Equity, Merchant & Venture Banking (MVB) at ThinkEquity, LLC. since February 2026 and leads the formation and strategic development of ThinkStern Ventures. Prior to ThinkEquity, he was CEO of SternAegis Ventures from December 2012 to February 2026 and had been the Head of Private Equity Banking at Aegis Capital Corp from December 2012 to February 2026. Prior to SternAegis, Mr. Stern served as Senior Managing Director at Spencer Trask Ventures, Inc., a private equity and venture firm, from 1997 to 2012, where he managed the structured finance group focusing primarily on technology and life sciences companies. From 1989 to 1997, Mr. Stern was at Josephthal & Co., Inc., Members of the New York Stock Exchange, where he served as Head of Private Equity and Managing Director. He has been a FINRA licensed securities broker since 1987 and a Registered General Securities Principal since 1991. Mr. Stern previously served as a director of VivoSim from February 2012 to June 2013. Mr. Stern is a current director at DarioHealth Corp. (Nasdaq: DRIO), privately held Amplifica Holdings, Group, Inc., and Aerami Therapeutics Holdings Inc. Mr. Stern is a former director of Adgero Biopharmaceuticals Holdings, Matinas BioPharma Holdings, Inc. (NYSE: MTNB), Hydrofarm Holdings Group Inc. (Nasdaq: HYFM), InVivo Therapeutics, Inc. (Nasdaq: NVIV) and PROLOR Biotech prior to its sale in 2013 to Opko Health, Inc. (Nasdaq: OPK). Mr. Stern graduated with a Bachelor of Arts degree from the University of South Florida in 1987.
高管简历
中英对照 | 中文 | 英文- Norman Staskey
Norman Staskey于2024年12月加入Vivosim Labs，Inc.。Staskey先生目前受雇于专业金融咨询服务公司Danforth Advisors，LLC（“Danforth”）。他拥有超过二十年的经验，自2021年5月以来一直在丹佛斯工作，担任他们的高级总监。Staskey先生是一位经验丰富的高管，在管理和领导团队以及监督私营和上市生命科学公司的财务和运营责任方面拥有丰富的经验。Staskey先生自2022年10月起担任Azitra，Inc.的首席财务官。2014年9月至2021年5月，Staskey先生受雇于安永（前身为安永），最近担任安永财务会计和咨询服务业务的董事总经理。Staskey先生在克利夫兰州立大学获得工商管理学士学位，是俄亥俄州的一名注册会计师。
Norman Staskey joined Vivosim Labs, Inc. in December 2024. Mr. Staskey is currently employed by Danforth Advisors, LLC ("Danforth"), a professional financial consulting services firm. He has over twenty years of experience and has been with Danforth since May 2021, serving as their Senior Director. Mr. Staskey is a seasoned executive with significant experience in managing and leading teams as well as overseeing the financial and operational responsibilities of private and publicly traded life sciences companies. Mr. Staskey has served as the Chief Financial Officer of Azitra, Inc. since October 2022. From September 2014 to May 2021, Mr. Staskey was employed by EY (formerly Ernst & Young), most recently as a managing director in EY's Financial Accounting and Advisory services practice. Mr. Staskey received his B.S. in Business Administration from Cleveland State University and is a Certified Public Accountant in the State of Ohio.- Norman Staskey于2024年12月加入Vivosim Labs，Inc.。Staskey先生目前受雇于专业金融咨询服务公司Danforth Advisors，LLC（“Danforth”）。他拥有超过二十年的经验，自2021年5月以来一直在丹佛斯工作，担任他们的高级总监。Staskey先生是一位经验丰富的高管，在管理和领导团队以及监督私营和上市生命科学公司的财务和运营责任方面拥有丰富的经验。Staskey先生自2022年10月起担任Azitra，Inc.的首席财务官。2014年9月至2021年5月，Staskey先生受雇于安永（前身为安永），最近担任安永财务会计和咨询服务业务的董事总经理。Staskey先生在克利夫兰州立大学获得工商管理学士学位，是俄亥俄州的一名注册会计师。
- Norman Staskey joined Vivosim Labs, Inc. in December 2024. Mr. Staskey is currently employed by Danforth Advisors, LLC ("Danforth"), a professional financial consulting services firm. He has over twenty years of experience and has been with Danforth since May 2021, serving as their Senior Director. Mr. Staskey is a seasoned executive with significant experience in managing and leading teams as well as overseeing the financial and operational responsibilities of private and publicly traded life sciences companies. Mr. Staskey has served as the Chief Financial Officer of Azitra, Inc. since October 2022. From September 2014 to May 2021, Mr. Staskey was employed by EY (formerly Ernst & Young), most recently as a managing director in EY's Financial Accounting and Advisory services practice. Mr. Staskey received his B.S. in Business Administration from Cleveland State University and is a Certified Public Accountant in the State of Ohio.
- Tony Lialin
Tony Lialin，曾担任DPBIO首席商务官。2025年4月至2025年6月担任Seonix Bio业务发展副总裁，2022年4月至2024年4月担任ONI销售与消费者成功副总裁。从2020年3月到2022年4月，Lialin先生担任Invivoscribe，Inc.的首席商务官。在该公司，他将领导进入市场的战略、合作伙伴关系以及公司基于圣地亚哥的服务的扩展，这些服务将器官特定的3D模型与人工智能驱动的分析相结合，以在开发早期提供决策就绪的洞察力。
Tony Lialin Chief Commercial Officer, joined Vivosim Labs, Inc. in August 2025. Mr. Lialin has more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. Prior to joining the Company, Mr. Lialin had served as Chief Commercial Officer of DPBIO from June 2025 to August 2025. From April 2025 to June 2025, he served as Vice President Business Development of Seonix Bio and from April 2022 to April 2024, he served as Vice President Sales & Consumer Success of ONI. From March 2020 to April 2022, Mr. Lialin served as Chief Commercial Officer of Invivoscribe, Inc.- Tony Lialin，曾担任DPBIO首席商务官。2025年4月至2025年6月担任Seonix Bio业务发展副总裁，2022年4月至2024年4月担任ONI销售与消费者成功副总裁。从2020年3月到2022年4月，Lialin先生担任Invivoscribe，Inc.的首席商务官。在该公司，他将领导进入市场的战略、合作伙伴关系以及公司基于圣地亚哥的服务的扩展，这些服务将器官特定的3D模型与人工智能驱动的分析相结合，以在开发早期提供决策就绪的洞察力。
- Tony Lialin Chief Commercial Officer, joined Vivosim Labs, Inc. in August 2025. Mr. Lialin has more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. Prior to joining the Company, Mr. Lialin had served as Chief Commercial Officer of DPBIO from June 2025 to August 2025. From April 2025 to June 2025, he served as Vice President Business Development of Seonix Bio and from April 2022 to April 2024, he served as Vice President Sales & Consumer Success of ONI. From March 2020 to April 2022, Mr. Lialin served as Chief Commercial Officer of Invivoscribe, Inc.
- Amar Sethi
Amar Sethi首席科学官，于2025年11月加入Vivosim Labs，Inc.。Sethi博士是一位转型研发主管，拥有三十年的经验，涵盖药物开发、CRO领导、转化医学和诊断创新。他领导了全球I – IV期临床项目、FDA突破和孤儿药指定、BLA申请，以及跨越代谢紊乱、肾脏病学、血液学、罕见病和心血管生物学的先进生物标志物战略。他的专长包括建立符合CAP/CLIA/GCP/GLP的基础设施，扩展生物分析和生物标志物团队，并指导早期和后期资产的科学战略。Sethi博士的职业生涯将药物开发领导地位与生物标志物创新联系起来。在加入公司之前，Sethi博士于2019年10月至2025年7月担任Omeros Corp临床科学副总裁，在那里他领导了一项突破性疗法/孤儿指定生物制剂的关键全球3期项目，并支持目前已获批准或进入后期阶段的多个单克隆抗体项目。作为Pacific Biomarkers的总裁兼首席医疗官，他推动了70%的业务增长，领导了成功的并购计划，并开发了FDA合格的新型生物标志物平台，包括FDA唯一合格的金标准急性肾损伤面板。他在美国国立卫生研究院和哥本哈根大学医院任职期间，进一步确立了他在临床化学、心脏代谢研究和转化诊断领域的科学权威地位。
Amar Sethi Chief Scientific Officer, joined Vivosim Labs, Inc. in November 2025. Dr. Sethi is a transformational R&D executive with three decades of experience encompassing pharmaceutical drug development, CRO leadership, translational medicine, and diagnostic innovation. He has led global Phase I–IV clinical programs, FDA breakthrough and orphan drug designations, BLA filings, and advanced biomarker strategies across metabolic disorders, nephrology, hematology, rare diseases, and cardiovascular biology. His expertise includes establishing CAP/CLIA/GCP/GLP compliant infrastructures, scaling bioanalytical and biomarker teams, and guiding scientific strategy for both early and late stage assets. Dr. Sethi's career bridges drug development leadership with biomarker innovation. Prior to joining the Company, Dr. Sethi served as Associate Vice President of Clinical Science at Omeros Corp from October 2019 to July 2025, where he led a pivotal global Phase 3 program for a Breakthrough Therapy/Orphan designated biologic and supported multiple monoclonal antibody programs now approved or advancing into late stages. As President & Chief Medical Officer of Pacific Biomarkers, he drove 70% business growth, led successful M&A initiatives, and developed FDA qualified novel biomarker platforms, including a gold standard Acute Kidney Injury panel uniquely qualified by the FDA. His tenure at NIH and Copenhagen University Hospitals further established him as a scientific authority in clinical chemistry, cardiometabolic research, and translational diagnostics.- Amar Sethi首席科学官，于2025年11月加入Vivosim Labs，Inc.。Sethi博士是一位转型研发主管，拥有三十年的经验，涵盖药物开发、CRO领导、转化医学和诊断创新。他领导了全球I – IV期临床项目、FDA突破和孤儿药指定、BLA申请，以及跨越代谢紊乱、肾脏病学、血液学、罕见病和心血管生物学的先进生物标志物战略。他的专长包括建立符合CAP/CLIA/GCP/GLP的基础设施，扩展生物分析和生物标志物团队，并指导早期和后期资产的科学战略。Sethi博士的职业生涯将药物开发领导地位与生物标志物创新联系起来。在加入公司之前，Sethi博士于2019年10月至2025年7月担任Omeros Corp临床科学副总裁，在那里他领导了一项突破性疗法/孤儿指定生物制剂的关键全球3期项目，并支持目前已获批准或进入后期阶段的多个单克隆抗体项目。作为Pacific Biomarkers的总裁兼首席医疗官，他推动了70%的业务增长，领导了成功的并购计划，并开发了FDA合格的新型生物标志物平台，包括FDA唯一合格的金标准急性肾损伤面板。他在美国国立卫生研究院和哥本哈根大学医院任职期间，进一步确立了他在临床化学、心脏代谢研究和转化诊断领域的科学权威地位。
- Amar Sethi Chief Scientific Officer, joined Vivosim Labs, Inc. in November 2025. Dr. Sethi is a transformational R&D executive with three decades of experience encompassing pharmaceutical drug development, CRO leadership, translational medicine, and diagnostic innovation. He has led global Phase I–IV clinical programs, FDA breakthrough and orphan drug designations, BLA filings, and advanced biomarker strategies across metabolic disorders, nephrology, hematology, rare diseases, and cardiovascular biology. His expertise includes establishing CAP/CLIA/GCP/GLP compliant infrastructures, scaling bioanalytical and biomarker teams, and guiding scientific strategy for both early and late stage assets. Dr. Sethi's career bridges drug development leadership with biomarker innovation. Prior to joining the Company, Dr. Sethi served as Associate Vice President of Clinical Science at Omeros Corp from October 2019 to July 2025, where he led a pivotal global Phase 3 program for a Breakthrough Therapy/Orphan designated biologic and supported multiple monoclonal antibody programs now approved or advancing into late stages. As President & Chief Medical Officer of Pacific Biomarkers, he drove 70% business growth, led successful M&A initiatives, and developed FDA qualified novel biomarker platforms, including a gold standard Acute Kidney Injury panel uniquely qualified by the FDA. His tenure at NIH and Copenhagen University Hospitals further established him as a scientific authority in clinical chemistry, cardiometabolic research, and translational diagnostics.
- Amar Sethi
Amar Sethi首席科学官，于2025年11月加入Vivosim Labs，Inc.。Sethi博士是一位转型研发主管，拥有三十年的经验，涵盖药物开发、CRO领导、转化医学和诊断创新。他领导了全球I – IV期临床项目、FDA突破和孤儿药指定、BLA申请，以及跨越代谢紊乱、肾脏病学、血液学、罕见病和心血管生物学的先进生物标志物战略。他的专长包括建立符合CAP/CLIA/GCP/GLP的基础设施，扩展生物分析和生物标志物团队，并指导早期和后期资产的科学战略。Sethi博士的职业生涯将药物开发领导地位与生物标志物创新联系起来。在加入公司之前，Sethi博士于2019年10月至2025年7月担任Omeros Corp临床科学副总裁，在那里他领导了一项突破性疗法/孤儿指定生物制剂的关键全球3期项目，并支持目前已获批准或进入后期阶段的多个单克隆抗体项目。作为Pacific Biomarkers的总裁兼首席医疗官，他推动了70%的业务增长，领导了成功的并购计划，并开发了FDA合格的新型生物标志物平台，包括FDA唯一合格的金标准急性肾损伤面板。他在美国国立卫生研究院和哥本哈根大学医院任职期间，进一步确立了他在临床化学、心脏代谢研究和转化诊断领域的科学权威地位。
Amar Sethi Chief Scientific Officer, joined Vivosim Labs, Inc. in November 2025. Dr. Sethi is a transformational R&D executive with three decades of experience encompassing pharmaceutical drug development, CRO leadership, translational medicine, and diagnostic innovation. He has led global Phase I–IV clinical programs, FDA breakthrough and orphan drug designations, BLA filings, and advanced biomarker strategies across metabolic disorders, nephrology, hematology, rare diseases, and cardiovascular biology. His expertise includes establishing CAP/CLIA/GCP/GLP compliant infrastructures, scaling bioanalytical and biomarker teams, and guiding scientific strategy for both early and late stage assets. Dr. Sethi's career bridges drug development leadership with biomarker innovation. Prior to joining the Company, Dr. Sethi served as Associate Vice President of Clinical Science at Omeros Corp from October 2019 to July 2025, where he led a pivotal global Phase 3 program for a Breakthrough Therapy/Orphan designated biologic and supported multiple monoclonal antibody programs now approved or advancing into late stages. As President & Chief Medical Officer of Pacific Biomarkers, he drove 70% business growth, led successful M&A initiatives, and developed FDA qualified novel biomarker platforms, including a gold standard Acute Kidney Injury panel uniquely qualified by the FDA. His tenure at NIH and Copenhagen University Hospitals further established him as a scientific authority in clinical chemistry, cardiometabolic research, and translational diagnostics.- Amar Sethi首席科学官，于2025年11月加入Vivosim Labs，Inc.。Sethi博士是一位转型研发主管，拥有三十年的经验，涵盖药物开发、CRO领导、转化医学和诊断创新。他领导了全球I – IV期临床项目、FDA突破和孤儿药指定、BLA申请，以及跨越代谢紊乱、肾脏病学、血液学、罕见病和心血管生物学的先进生物标志物战略。他的专长包括建立符合CAP/CLIA/GCP/GLP的基础设施，扩展生物分析和生物标志物团队，并指导早期和后期资产的科学战略。Sethi博士的职业生涯将药物开发领导地位与生物标志物创新联系起来。在加入公司之前，Sethi博士于2019年10月至2025年7月担任Omeros Corp临床科学副总裁，在那里他领导了一项突破性疗法/孤儿指定生物制剂的关键全球3期项目，并支持目前已获批准或进入后期阶段的多个单克隆抗体项目。作为Pacific Biomarkers的总裁兼首席医疗官，他推动了70%的业务增长，领导了成功的并购计划，并开发了FDA合格的新型生物标志物平台，包括FDA唯一合格的金标准急性肾损伤面板。他在美国国立卫生研究院和哥本哈根大学医院任职期间，进一步确立了他在临床化学、心脏代谢研究和转化诊断领域的科学权威地位。
- Amar Sethi Chief Scientific Officer, joined Vivosim Labs, Inc. in November 2025. Dr. Sethi is a transformational R&D executive with three decades of experience encompassing pharmaceutical drug development, CRO leadership, translational medicine, and diagnostic innovation. He has led global Phase I–IV clinical programs, FDA breakthrough and orphan drug designations, BLA filings, and advanced biomarker strategies across metabolic disorders, nephrology, hematology, rare diseases, and cardiovascular biology. His expertise includes establishing CAP/CLIA/GCP/GLP compliant infrastructures, scaling bioanalytical and biomarker teams, and guiding scientific strategy for both early and late stage assets. Dr. Sethi's career bridges drug development leadership with biomarker innovation. Prior to joining the Company, Dr. Sethi served as Associate Vice President of Clinical Science at Omeros Corp from October 2019 to July 2025, where he led a pivotal global Phase 3 program for a Breakthrough Therapy/Orphan designated biologic and supported multiple monoclonal antibody programs now approved or advancing into late stages. As President & Chief Medical Officer of Pacific Biomarkers, he drove 70% business growth, led successful M&A initiatives, and developed FDA qualified novel biomarker platforms, including a gold standard Acute Kidney Injury panel uniquely qualified by the FDA. His tenure at NIH and Copenhagen University Hospitals further established him as a scientific authority in clinical chemistry, cardiometabolic research, and translational diagnostics.
- Keith Murphy
Keith Murphy，重新加入Organovo Holdings， Inc.。他曾担任Organovo Holdings， Inc.的董事。自2020年9月起担任执行主席。他是Viscient Biosciences， Inc.（“Viscient”）的首席执行官兼董事长，这是他于2017年创立的一家私营公司，专注于利用3D组织技术和多组学（基因组学、转录组学、代谢组学）的药物发现和开发。2012年2月至2017年4月，他担任Organovo的总裁兼首席执行官；2012年2月至2017年8月，担任董事长。2007年8月至2012年2月，他曾担任Organovo， Inc. （Organovo的主要运营公司，上市交易前）的总裁、首席执行官和董事长。在创立Organovo之前，从1997年8月到2007年7月，Murphy先生在Amgen， Inc.担任各种职务，包括骨质疏松症/骨癌药物Prolia/Xgeva （denosumab）的全球运营主管。加入Amgen之前，从1993年7月到1997年7月，Murphy先生在Alkermes， Inc.（生物技术公司）任职，在那里他担任他们的第一个批准产品Nutropin （hGH） Depot的开发团队的角色。Murphy先生从2020年8月到2022年2月担任Kintara Therapeutics， Inc.的董事会成员，并在其薪酬委员会、提名和公司治理委员会任职。他持有麻省理工学院化学工程学士学位，是加州大学洛杉矶分校安德森管理学院的校友。
Keith Murphy re joined the company's Board in July 2020 and has served as the company's Executive Chairman since September 2020. Mr. Murphy is the Chief Executive Officer and Chairman of Viscient Biosciences, Inc. ("Viscient"), a private company that he founded in 2017 that is focused on drug discovery and development utilizing 3D tissue technology and multi omics (genomics, transcriptomics, metabolomics). Mr. Murphy previously served as the company's President and Chief Executive Officer from February 2012 through April 2017, and as Chairman from February 2012 through August 2017. Mr. Murphy also previously served as President, Chief Executive Officer, and Chairman of Organovo, Inc., the company's primary operating company prior to its going public transaction, from August 2007 to February 2012. Prior to founding Organovo, Inc., Mr. Murphy served in various roles at Amgen, Inc. from August 1997 to July 2007 including as Global Operations Leader for the osteoporosis/bone cancer drug Prolia/Xgeva (denosumab). Prior to joining Amgen, Mr. Murphy served at Alkermes, Inc., a biotechnology company, from July 1993 to July 1997, where he played a role on the development team for their first approved product, Nutropin (hGH) Depot. Mr. Murphy has served as a member of the board of directors of Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) since March 2025 and served as a member of the board of directors of Kintara Therapeutics, Inc. from August 2020 to February 2022, and served on its compensation committee and nominating and corporate governance committee. He holds a B.S. in Chemical Engineering from MIT and is an alumnus of the UCLA Anderson School of Management.- Keith Murphy，重新加入Organovo Holdings， Inc.。他曾担任Organovo Holdings， Inc.的董事。自2020年9月起担任执行主席。他是Viscient Biosciences， Inc.（“Viscient”）的首席执行官兼董事长，这是他于2017年创立的一家私营公司，专注于利用3D组织技术和多组学（基因组学、转录组学、代谢组学）的药物发现和开发。2012年2月至2017年4月，他担任Organovo的总裁兼首席执行官；2012年2月至2017年8月，担任董事长。2007年8月至2012年2月，他曾担任Organovo， Inc. （Organovo的主要运营公司，上市交易前）的总裁、首席执行官和董事长。在创立Organovo之前，从1997年8月到2007年7月，Murphy先生在Amgen， Inc.担任各种职务，包括骨质疏松症/骨癌药物Prolia/Xgeva （denosumab）的全球运营主管。加入Amgen之前，从1993年7月到1997年7月，Murphy先生在Alkermes， Inc.（生物技术公司）任职，在那里他担任他们的第一个批准产品Nutropin （hGH） Depot的开发团队的角色。Murphy先生从2020年8月到2022年2月担任Kintara Therapeutics， Inc.的董事会成员，并在其薪酬委员会、提名和公司治理委员会任职。他持有麻省理工学院化学工程学士学位，是加州大学洛杉矶分校安德森管理学院的校友。
- Keith Murphy re joined the company's Board in July 2020 and has served as the company's Executive Chairman since September 2020. Mr. Murphy is the Chief Executive Officer and Chairman of Viscient Biosciences, Inc. ("Viscient"), a private company that he founded in 2017 that is focused on drug discovery and development utilizing 3D tissue technology and multi omics (genomics, transcriptomics, metabolomics). Mr. Murphy previously served as the company's President and Chief Executive Officer from February 2012 through April 2017, and as Chairman from February 2012 through August 2017. Mr. Murphy also previously served as President, Chief Executive Officer, and Chairman of Organovo, Inc., the company's primary operating company prior to its going public transaction, from August 2007 to February 2012. Prior to founding Organovo, Inc., Mr. Murphy served in various roles at Amgen, Inc. from August 1997 to July 2007 including as Global Operations Leader for the osteoporosis/bone cancer drug Prolia/Xgeva (denosumab). Prior to joining Amgen, Mr. Murphy served at Alkermes, Inc., a biotechnology company, from July 1993 to July 1997, where he played a role on the development team for their first approved product, Nutropin (hGH) Depot. Mr. Murphy has served as a member of the board of directors of Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) since March 2025 and served as a member of the board of directors of Kintara Therapeutics, Inc. from August 2020 to February 2022, and served on its compensation committee and nominating and corporate governance committee. He holds a B.S. in Chemical Engineering from MIT and is an alumnus of the UCLA Anderson School of Management.